보고서 요약(국문)

시장 개요
전 세계 신장암 및 신세포암 치료제 시장은 2022년 56억 달러 규모에 달했으며, 2030년까지 89억 달러 규모로 성장할 것으로 예상됩니다. 전 세계 신장암 및 신세포암 치료제 시장은 예측 기간(2023-2030년) 동안 연평균 6.3%의 성장률을 보일 것으로 전망됩니다.
제약 회사와 연구 기관들은 신약 개발 및 신장암 치료 전략에 상당한 투자를 하고 있습니다. 이러한 지속적인 연구 개발 활동을 통해 더욱 발전되고 강력한 치료제들이 시장에 출시될 것으로 예상되며, 이는 향후 시장 성장을 촉진할 것입니다.
시장 동향
주요 업체들의 적극적인 활동이 예측 기간 동안 전 세계 신장암 및 신세포암 치료제 시장 성장을 견인할 것으로 예상됩니다.
2022년 10월, Aveo Oncology는 신장암 치료제 Fotivda의 FDA 승인을 앞두고 새로운 방향을 모색했습니다. LG화학은 아베오의 인수 덕분에 포티브다(Fotivda)를 비롯한 아베오의 다른 항암제 후보 물질 개발에 더욱 박차를 가할 수 있을 것으로 기대하고 있습니다. 아베오는 포티브다 외에도 세 가지 항암제 후보 물질을 보유하고 있으며, 포티브다는 지난 3월 FDA로부터 재발성 또는 내성 진행성 신세포암 3차 치료제로 예상치 못한 승인을 받았습니다.
아베오는 최근 2028년 만료 예정이었던 포티브다 특허를 2039년까지 연장할 수 있다는 사실을 확인했으며, 이는 LG화학에게 더욱 유리하게 작용할 것으로 보입니다.
맞춤형 의약품 개발은 신장암 및 신세포암 치료제 시장의 성장 기회를 제공합니다.
맞춤형 의약품 기술은 신장암의 유전적, 분자적 측면에 대한 이해가 깊어짐에 따라 발전해 왔습니다. 맞춤형 치료 계획을 수립하기 위해 유전자 검사 및 바이오마커 분석을 통해 종양 내 특정 돌연변이 또는 이상을 찾아낼 수 있습니다. 특정 유전적 결함을 표적으로 하는 약물은 맞춤형 치료에 대한 관심이 높아짐에 따라 수요가 증가하고 있으며, 이는 시장 확대를 견인하고 있습니다.

맞춤형 의학 덕분에 신장암 및 신세포암(RCC)과 관련된 특정 분자 표적을 구체적으로 공략하는 표적 치료제가 개발되었습니다. 면역 체크포인트 억제제와 티로신 키나제 억제제(TKI)와 같은 이러한 약물은 종양의 발생 및 생존에 필수적인 특정 분자 또는 경로를 차단하도록 만들어졌습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 신장암 및 신세포암 치료제 시장에 상당한 영향을 미쳤습니다. 팬데믹은 전 세계 물류 및 공급망에 영향을 미쳐 특히 신장암 및 신세포암 치료에 필요한 의약품의 접근성을 저해했습니다. 중요한 의약품의 안정적인 공급을 유지하기 위한 노력에도 불구하고, 때때로 공급 부족과 배송 지연이 발생했습니다. 또한 국경 폐쇄 및 운송 제한으로 인해 의약품의 수출입이 제한되어 일부 지역에서는 의약품 접근성이 저하되었을 수 있습니다.
2023년 현재, COVID-19 상황이 회복되고 모든 환자가 의료 시설을 이용할 수 있게 되면서 신장암 및 신세포암 치료제에 대한 수요가 증가하고 있습니다.

러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁이 신장암 및 신세포암 치료제 시장에 미치는 영향은 복잡하고 다면적입니다. 이 분쟁은 의료 시스템에 부담을 주어 암 치료와 같은 전문 치료에 대한 자원과 관심을 분산시킬 수 있습니다. 최상의 치료를 제공하는 데 있어 병원 및 의료 시설은 전문 의약품 접근성을 포함한 여러 문제에 직면할 수 있습니다.
세분화 분석
전 세계 신장암 및 신세포암 치료제 시장은 제품, 최종 사용자, 유통 채널 및 지역별로 세분화됩니다.
에베롤리무스 부문은 예측 기간 동안 시장에서 중요한 위치를 차지할 것으로 예상됩니다.
에베롤리무스 부문은 2022년 신장암 및 신세포암 치료제 시장에서 약 22.3%의 점유율을 차지하며 가장 높은 시장 점유율 중 하나를 기록했습니다. 에베롤리무스는 세포 성장, 증식 및 신생혈관 생성(새로운 혈관 형성)을 조절하는 데 관여하는 mTOR 경로를 억제함으로써 작용합니다. 에베롤리무스는 mTOR을 억제하여 암세포의 성장을 늦추고 종양에 영양분을 공급하는 새로운 혈관 생성을 억제합니다. 에베롤리무스는 진행성 신세포암(RCC) 치료를 위해 단독 요법 또는 다른 약물과의 병용 요법으로 사용할 수 있습니다.
지역 분석
신장암 환자 수 증가, FDA 승인, 신장암 및 신세포암 치료제 개발의 진전으로 유럽 지역이 시장을 주도하고 있습니다.
유럽은 신장암 및 신세포암 치료제 시장의 약 27.9%를 차지하며 시장을 주도할 것으로 예상됩니다. 유럽 국가별로 신장암, 특히 신세포암(RCC) 발병률은 다릅니다. 매년 11만 5천 건 이상의 사례가 발생하고 4만 9천 명이 사망하는 신장암은 유럽에서 다섯 번째로 흔한 악성 종양입니다.
유럽은 전 세계에서 65세 이상 인구가 가장 많은 지역입니다. 신장암 발병률은 나이가 들수록 증가하는 경향이 있으며, 고령화는 질병의 전반적인 유병률을 높이는 요인입니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Roche Inc, GlaxoSmithKline Plc., Active Biotech Ab., Heidelberg Pharma AG, Inc., Bristol-Myers Squibb, Eisai, Exelixis, Novartis AG, Amgen, Bayer AG 등이 있습니다.
보고서 구매 이유

• 제품, 최종 사용자, 유통 채널 및 지역별 글로벌 신장암 및 신세포암 치료제 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 신장암 및 신세포암 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 신장암 및 신세포암 치료제 시장 보고서는 약 61개의 표, 63개의 그림, 그리고 195페이지 분량으로 구성됩니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Kidney Cancer and Renal Cell Carcinoma Drugs Market reached US$ 5.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 8.9 billion by 2030. The global kidney cancer and renal cell carcinoma drugs market is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030).
The development of novel medications and kidney cancer treatment strategies is receiving significant funding from pharmaceutical corporations and research organizations. The introduction of additional cutting-edge and potent medications to the market is anticipated to result from this ongoing research and development activity, spurring future expansion.
Market Dynamics
Active Major Players Are Boosting The Global Kidney Cancer And Renal Cell Carcinoma Drugs Market Growth During The Forecast Period.
In October 2022, on the approach to receiving FDA approval for its kidney cancer medication Fotivda, Aveo Oncology took a diversion. LG Chem now intends to have better success developing Fotivda and Aveo's other cancer candidates due to Aveo's acquisition of LG Chem. Aveo has three other cancer candidates in addition to Fotivda, which was unexpectedly approved by the FDA in March for the third-line treatment of advanced renal cell carcinoma that has relapsed or is resistant.
Aveo recently found that its patent on Fotivda, set to expire in 2028, could really be extended all the way to 2039, making it more desirable for LG Chem.
The Development Of Personalized Medicines Provides Kidney Cancer And Renal Cell Carcinoma Drug Market Growth Opportunities.
Personalized medicine techniques have been created as a result of our growing understanding of the genetic and molecular aspects of kidney cancer. In order to develop customized treatment plans, genetic testing, and biomarker analyses help detect certain mutations or abnormalities in tumors. Drugs that target particular genetic defects are in high demand due to the focus on personalized therapy, which is propelling market expansion.
Targeted medicines that specifically tackle particular molecular targets involved in kidney cancer and RCC have been made possible by personalized medicine. These medications, such as immune checkpoint inhibitors and tyrosine kinase inhibitors (TKIs), are made to block particular molecules or pathways that are essential for the development and survival of tumors.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the kidney cancer and renal cell carcinoma drugs market. The pandemic has impacted worldwide logistics and supply chains, which has caused disruptions in the accessibility of drugs, especially those required to treat kidney cancer and RCC. Despite efforts to keep a consistent supply of important pharmaceuticals, there have occasionally been shortages and delays in their delivery. Additionally, border closures and limits on transportation may have hindered the import and export of pharmaceuticals, which could have hampered access in some regions.
As of 2023, the COVID-19 situation is recovering and all patients can access the healthcare facilities leading to increasing demand for kidney cancer and renal cell carcinoma drugs.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the kidney cancer and renal cell carcinoma drugs market is complex and multifaceted. The dispute may put a strain on the healthcare system, taking resources and focus away from specialized treatments like cancer therapy. Providing the best care may present issues for hospitals and healthcare facilities, including access to specialized medications.
Segment Analysis
The global kidney cancer and renal cell carcinoma drugs market is segmented based on product, end-user, distribution channel, and region.
The Everolimus Segment Is Expected To Hold A Position In The Market Over The Forecast Period.
The Everolimus segment accounted for one of the highest market stake accounting for approximately 22.3% of the kidney cancer and renal cell carcinoma drugs market in 2022. Everolimus works by inhibiting the mTOR pathway, which is involved in regulating cell growth, proliferation, and angiogenesis (the formation of new blood vessels). By inhibiting mTOR, Everolimus helps slow down the growth of cancer cells and prevents the formation of new blood vessels that supply nutrients to the tumor. Everolimus can be used as a single agent or in combination with other drugs for the treatment of advanced RCC.
Geographical Analysis
An Increasing Number Of Patients With Kidney Cancer, FDA Approvals, And Advancement In Kidney Cancer And Renal Cell Carcinoma Drugs Dominate The European Region.
Europe is expected to dominate the kidney cancer and renal cell carcinoma drugs market, accounting for around 27.9% of this market. Different European nations have different rates of kidney cancer, particularly renal cell carcinoma (RCC). With more than 115,000 cases identified each year and 49,000 fatalities, kidney cancer is the fifth most prevalent malignancy in Europe.
In Europe, there are more people over the age of 65 than anywhere else in the world. The incidence of kidney cancer tends to rise with age, and the aging population adds to the disease's overall prevalence.
Competitive Landscape
The major global players in the market include Roche Inc, GlaxoSmithKline Plc., Active Biotech Ab., Heidelberg Pharma AG, Inc., Bristol-Myers Squibb, Eisai, Exelixis, Novartis AG, Amgen, and Bayer AG among others.
Why Purchase the Report?
• To visualize the global kidney cancer and renal cell carcinoma drugs market segmentation based on the product, end-users, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous kidney cancer and renal cell carcinoma drugs market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global kidney cancer and renal cell carcinoma drugs market report would provide approximately 61 tables, 63 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by End-users
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing incidences of kidney and RCC cases
4.1.2. Restraints
4.1.2.1. Side effects associated with These Drugs
4.1.3. Opportunity
4.1.3.1. Research and development
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Product
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.1.2. Market Attractiveness Index, By Product
9.2. Bevacizumab*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Everolimus
9.4. Cabozantinib
9.5. Axitinib
9.6. Sorafenib
9.7. Temsirolimus
9.8. Sunitinib
9.9. Pazopanib
10. By End-users
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
10.1.2. Market Attractiveness Index, By End-users
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers
10.4. Specialty Clinics
10.5. Others
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. The U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. The U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. Roche Inc*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. GlaxoSmithKline Plc.
14.3. Active Biotech Ab
14.4. Heidelberg Pharma AG, Inc.
14.5. Bristol-Myers Squibb
14.6. Eisai
14.7. Exelixis.,
14.8. Novartis AG
14.9. Amgen
14.10. Bayer AG
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Roche Inc, 4.	Key Developments, GlaxoSmithKline Plc., Active Biotech Ab, Heidelberg Pharma AG, Inc., Bristol-Myers Squibb, Eisai, Exelixis.,, Novartis AG, Amgen, Bayer AG

표 목록 (Tables)

List of Tables

Table 1 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Product Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By End-users, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Product Type, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 7 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By End-users, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By End-users, 2021-2030 (US$ Billion)

Table 9 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 11 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 14 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By End-users, 2021-2030 (US$ Billion)

Table 15 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 16 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 18 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By End-users, 2021-2030 (US$ Billion)

Table 19 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 22 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By End-users, 2021-2030 (US$ Billion)

Table 23 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 24 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By End-users, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By End-users, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 32 Roche Inc: Overview

Table 33 Roche Inc: Product Portfolio

Table 34 Roche Inc: Key Developments

Table 35 GlaxoSmithKline Plc.: Overview

Table 36 GlaxoSmithKline Plc.: Product Portfolio

Table 37 GlaxoSmithKline Plc.: Key Developments

Table 38 Active Biotech Ab.: Overview

Table 39 Active Biotech Ab.: Product Portfolio

Table 40 Active Biotech Ab.: Key Developments

Table 41 Heidelberg Pharma AG, Inc: Overview

Table 42 Heidelberg Pharma AG, Inc: Product Portfolio

Table 43 Heidelberg Pharma AG, Inc: Key Developments

Table 44 Bristol-Myers Squibb: Overview

Table 45 Bristol-Myers Squibb: Product Portfolio

Table 46 Bristol-Myers Squibb: Key Developments

Table 47 Eisai: Overview

Table 48 Eisai: Product Portfolio

Table 49 Eisai: Key Developments

Table 50 Exelixis: Overview

Table 51 Exelixis: Product Portfolio

Table 52 Exelixis: Key Developments

Table 53 Novartis AG.: Overview

Table 54 Novartis AG.: Product Portfolio

Table 55 Novartis AG.: Key Developments

Table 56 Amgen: Overview

Table 57 Amgen: Product Portfolio

Table 58 Amgen: Key Developments

Table 59 Bayer AG: Overview

Table 60 Bayer AG: Product Portfolio

Table 61 Bayer AG: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 3 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By End-users, 2022 & 2030 (%)

Figure 4 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Y-o-Y Growth, By Product Type, 2022-2030 (%)

Figure 7 Bevacizumab Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 8 Everolimus Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 9 Cabozantinib Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 10 Axitinib Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 11 Sorafenib Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 12 Temsirolimus Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 13 Sunitinib Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 14 Pazopanib Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 15 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Y-o-Y Growth, By End-users, 2022-2030 (%)

Figure 16 Hospitals End-users in Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 17 Ambulatory Surgical Centers End-users in Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 19 Specialty Centers End-users in Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 20 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 21 Hospital Pharmacies Distribution Channel in Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 22 Retail Pharmacies Distribution Channel in Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 23 Online Pharmacies Distribution Channel in Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 24 Global Kidney Cancer and Renal Cell Carcinoma Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 26 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 27 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 28 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 29 Middle East and Africa Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 30 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 31 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 32 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By End-users, 2022 & 2030 (%)

Figure 33 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 34 North America Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 35 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 36 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 37 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By End-users, 2022 & 2030 (%)

Figure 38 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 39 South America Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 40 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 41 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 42 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By End-users, 2022 & 2030 (%)

Figure 43 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 44 Europe Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 45 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 46 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 47 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By End-users, 2022 & 2030 (%)

Figure 48 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 49 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 50 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma Drugs Market Value, 2021-2030 (US$ Billion)

Figure 51 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 52 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By End-users, 2022 & 2030 (%)

Figure 53 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 54 Roche Inc: Financials

Figure 55 GlaxoSmithKline Plc.: Financials

Figure 56 Active Biotech Ab.: Financials

Figure 57 Heidelberg Pharma AG, Inc: Financials

Figure 58 Bristol-Myers Squibb: Financials

Figure 59 Eisai: Financials

Figure 60 Exelixis: Financials

Figure 61 Novartis AG: Financials

Figure 62 Amgen: Financials

Figure 63 Bayer AG: Financials

세계 신장암 및 신세포암 치료제 시장 – 2023-2030

Global Kidney Cancer and Renal Cell Carcinoma Drugs Market - 2023-2030